Nxera Pharma Co. Ltd, formerly known as Sosei Group, announced that its operating business Nxera Pharma Korea has reached an exclusive supply and distribution agreement with Handok Inc. to commercialize PIVLAZ (clazosentan sodium) 150 mg in South Korea.
PIVLAZ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage. PIVLAZ will become commercially available in South Korea in early 2025, Nxera Pharma said in a statement.
As per the terms of the agreement, Nxera Pharma Korea will provide drug product to Handok at an agreed price and Handok is exclusively responsible for the promotion, marketing, sales and distribution of PIVLAZ in South Korea. Nxera will receive a one-off upfront payment from Handok upon signing of the agreement and is eligible for further commercial milestone payments plus sales coming from product supply.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.